Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis have?
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis has 399 citations in the OpenAlex counts ScholarIQ stores.
When was Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis published?
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis has 2020 year in the ScholarIQ index.
What is the open-access status of Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis?
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis has hybrid oa status in the ScholarIQ index.
What is the DOI of Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis?
The DOI for Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis is on the source record.
What is the PMID of Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis?
The PMID for Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis is on the source record.
What is the OpenAlex record for Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis?
The OpenAlex for Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis is on the source record.